Enabling Capacity Expansion for a Pharma Ancillary Company

Background

A specialized pharmaceutical ancillary company had built a strong presence supplying critical inputs and value-added solutions to leading Indian pharma manufacturers. To capture sector growth and strengthen infrastructure, the company required structured public-market funding.

Challenge

Despite operational strength, the promoters were new to capital markets and required end-to-end guidance on compliance, investor positioning, and listing processes.

Lorvet’s Role

Initiated strategic discussions on the SME IPO as a viable fundraising pathway.
Conducted a detailed business and financial review to identify key metrics and sector drivers.
Collaborated with merchant bankers and auditors to prepare comprehensive DRHP disclosures highlighting operational capabilities and industry positioning.
Managed coordination among merchant banker, Company Secretary, and Chartered Accountants for smooth documentation and regulatory compliance.
Facilitated stock-exchange communication and ensured timely responses to regulatory scrutiny
Supported the company through investor roadshows, subscription, and listing phases.
Provided ongoing post-listing advisory on governance, filings, and investor communication

Outcome

A successful SME IPO enabled the company to raise growth capital, strengthen operational capacity, and enhance its visibility within the pharmaceutical supply-chain ecosystem.

EXPLORE OTHER
CASE STUDIES

Successful mandates that highlight our expertise

Scaling a Circular Economy Enterprise

We helped the company complete feasibility, documentation, and regulatory coordination for a smooth SME IPO journey.

Strategic SME IPO advisory

Robust regulatory and DRHP execution